Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb

Rhea-AI Summary

Scinai Immunotherapeutics (NASDAQ: SCNI) has received positive regulatory feedback from the Paul Erlich Institute (PEI) for its anti-IL-17A/F nanoAb (SCN-1) drug development program in Plaque Psoriasis. Key points include:

1. Toxicology studies can be conducted in pigs instead of non-human primates.
2. Phase 1/2a clinical trial can assess both safety and efficacy, skipping healthy volunteer testing.
3. Comparison of SCN-1 to placebo on the same human subject is approved.
4. Manufacturing process and specifications are deemed acceptable.

The Phase 1/2a study, expected to include 24 patients, is planned for the second half of 2025 with results in 2026. This feedback could lead to significant time and cost savings in Scinai's drug development plans for mild to moderate plaque psoriasis treatment.

Positive

• Positive regulatory feedback from PEI for anti-IL-17A/F nanoAb (SCN-1) drug development program
• Approval to conduct toxicology studies in pigs instead of non-human primates, potentially reducing time and costs
• Acceptance of combined Phase 1/2a clinical trial design, assessing both safety and efficacy
• Approval to compare SCN-1 to placebo on the same human subject, potentially reducing required patient numbers
• Manufacturing process and specifications deemed acceptable by PEI
• Potential time and cost savings in drug development plans

Negative

• Phase 1/2a clinical trial not expected to commence until second half of 2025, with results in 2026

Insights

Medical Research Analyst

The positive regulatory feedback from the Paul Erlich Institute (PEI) is a significant milestone for Scinai Immunotherapeutics. The affirmation to proceed with Phase 1/2a trials for SCN-1, targeting plaque psoriasis, is notable. Plaque psoriasis is a condition with substantial unmet medical needs, affecting millions globally. The PEI's acceptance to use pigs for toxicology studies, bypass clinic trials in healthy volunteers and directly compare SCN-1 to placebo within the same patients are regulatory accommodations that may expedite the development pipeline.

This regulatory green light not only saves time and cost but also reinforces the potential efficacy of SCN-1. For investors, this progression indicates the company's solid groundwork and increasing viability of its product in addressing a prevalent dermatological condition. Moreover, the PEI's comments on manufacturing capabilities boost confidence in Scinai's operational competencies.

Market Research Analyst

The feedback from the PEI is a promising development for Scinai, signaling a positive future for their anti-IL-17 nanoAb. The global market for plaque psoriasis treatments is substantial, with an estimated 13 million patients in key markets. Current treatments for mild to moderate plaque psoriasis often result in low patient adherence due to frequent application needs and side effects. Scinai's product, designed for local and less frequent administration, could capture significant market share if it proves effective and safe in trials.

The anticipated cost savings in the development process, due to regulatory leniencies, position Scinai to potentially allocate resources more efficiently and bring the product to market faster. For retail investors, these developments suggest a potentially lucrative investment opportunity as the company moves closer to clinical validation and market entry.

Financial Analyst

From a financial perspective, the regulatory feedback from the PEI significantly de-risks Scinai's development plan for SCN-1. The cost and time efficiencies gained through strategic decisions, such as the use of pigs for toxicology studies and skipping healthy volunteer trials, are critical. These measures could reduce the overall financial burden and accelerate the path to market, directly impacting the company’s bottom line and future revenue potential.

The acknowledgment of the manufacturing process and the streamlined trial approach are positive indicators. Investors should note that the faster timeline to Phase 1/2a trials reduces the time to potential revenue generation. Additionally, the regulatory feedback provides a solid foundation for Scinai's credibility, which could positively influence stock performance and valuation.

Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the Paul Erlich Institute (the PEI) for its drug development program towards Phase 1/2a clinical trial of its anti-IL-17A/F nanoAb (SCN-1) in Plaque Psoriasis

• Clarified preclinical toxicology and clinical program for Plaque Psoriasis First-in-human with intralesional injections for the treatment of patients with mild to moderate Plaque Psoriasis
• The PEI had requested to see data of efficacy in blocking IL-17F; this data became available as per the Company's announcement last week describing the positive in vivo proof of concept results.
• The PEI accepted the Company's position that toxicology studies can be conducted in pigs rather than in Non-Human Primates.
• The PEI accepted the Company's position to compare the SCN-1 to placebo directly in patients with mild to moderate plaque psoriasis while skipping the need for testing in healthy volunteers, resulting in a phase 1/2a clinical trial, which will assess both safety and efficacy in the same trial.
• The PEI agreed to compare SCN-1 to placebo on the same human subject, a strategy that could significantly reduce the number of patients required for the clinical trial
• The PEI commented that the manufacturing process looks well developed and that controls and specifications presented are acceptable
• The Phase 1/2a study is expected to include approximately 24 plaque psoriasis patients and is expected to commence in the second half of 2025 with readout in 2026.

JERUSALEM, July 23, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) (the "Company"), a biotechnology company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced the receipt of minutes of meeting from a recent Scientific Advice ("SA") with the Paul Erlich Institute, Federal Institute for Vaccines and Biomedicines (the "PEI"), which is considered acceptable guidance for IMPD filing with the European Medicines Agency (EMA) and is also considered the European comparable to a pre-IND meeting with the FDA in the U.S. The Company believes that the minutes of meeting reflect positive regulatory feedback, which can be translated into significant time and cost savings in its IL-17 nanoAb drug development plans.

On June 4, 2024, Scinai's scientific team met, over a video conference, with representatives of the PEI for a pre-scheduled, official, Scientific Advisory meeting during which Scinai presented its drug development plan of its novel anti-IL-17A/F nanoAb for the treatment of mild to moderate plaque psoriasis and asked the PEI for guidance and advice on various aspects.

The Meeting

In the meeting, Scinai presented its Chemistry Manufacturing and Controls package, its results from non-clinical ex-vivo and in-vivo studies and its plans for toxicology and first-in-human clinical trial. In addition, Scinai presented the advantages in developing an anti-IL-17 nanoAb for local administration into the psoriatic lesions and the unmet medical need for the intended indication of patients with mild to moderate psoriasis. Scinai indicated that localized treatments to date, including corticosteroid-based creams/ointments and phototherapy require far more intense treatment regimens. These treatments require either more frequent applications (corticosteroids twice a day and biologics once a month) or more frequent visits to the clinic (phototherapy). It is expected that the biological activity of Scinai's nanoAb will last well after the treatment which would potentially result in a far less demanding treatment regimen. Moreover, as a considerable proportion of patients with mild-moderate psoriasis do not respond well to treatments that are intended for mild to moderate psoriasis (corticosteroids, phototherapy) and are treated with biological (mAbs), the unmet need appears well established.

Taken together, it was agreed by the PEI that the results of the non-clinical Proof of Concept (PoC) study (results which were announced on July 15^th, 2024) and clinical explorations will shed further light on the suitability of intended localized treatment setting and regimen for Scinai's nanoAb.

Overall, the PEI commented that the manufacturing process looks well developed, that the in-process controls and the Drug Substance (DS) and Drug Product (DP) specifications are all acceptable. The PEI accepted the Company's approach that for local treatment, conducting toxicology studies in pigs rather than in Non-Human Primates is acceptable. This would translate to a significant time and cost saving for the Company. Additionally, the PEI was in agreement with the proposed design for the clinical trial and its definition as phase 1/2a trial, as it will evaluate both safety and efficacy. They supported the recruitment of mild to moderate plaque psoriasis patients (skipping the evaluation of the NanoAb in healthy volunteers) and comparing the NanoAb to placebo. Again, this will speed up the recruitment stage and lessen the cost. For correct intra-patient comparison, the PEI recommended ensuring a similar lesion size in the experimental and control groups.

Upon receiving the above guidance from the PEI, the Company expects to commence preparations for a pre-clinical toxicology study before commencing a first-in-human clinical trial of its anti-IL 17 NanoAbs for the treatment of plaque psoriasis in 2025.

The unmet market need

Today, there are about 13 million patients diagnosed with plaque psoriasis in the 7 major markets (US, EU5 and Japan). 50% of all psoriasis patients suffer from mild disease and about 28% suffer from moderate psoriasis¹. Patients diagnosed with mild to moderate plaque psoriasis often suffer from considerable and visible lesions which may be uncomfortable, painful, and have a negative impact on their social and mental well-being, especially when the lesions are located on the face, genitals, scalp, palms of hands, and bottom of feet. The therapeutics for mild to moderate plaque psoriasis include mostly corticosteroids, applied topically, and phototherapy. These treatments require very frequent use, have risks for local adverse effects such as skin atrophy and development of tolerance, and suffer from low patient adherence to treatment schedule. The current therapeutics for moderate to severe disease include mostly biologics and JAK inhibitors. While highly efficacious, these treatments are administered systemically, are highly expensive and require chronic use, which carries long term health risks and considerable economic burden to the patients and the health care system. Therefore, treatment of mild to moderate plaque psoriasis is suboptimal and can be improved.

Scinai's product candidate is designed to address the major shortcomings of currently available treatments. It is a biologic, intended to be delivered locally, intradermally, into the psoriatic lesions using a very short and almost painless needle. Scinai's product is designed to allow patients with mild to moderate psoriasis to benefit from a low frequency treatment that comes with the high specificity and potency saved for biologics but with significantly reduced risk of local side effects associated with corticosteroids or systemic side effects associated with systemic administration of biologics.

Dr. Tamar Ben-Yedidia, Scinai's Chief Scientist, noted, "It is encouraging to receive such a supportive regulatory summary for our plans. The PEI agreed with the unmet need of the patients with mild-to-moderate psoriasis for a better therapy and accepted our pre-clinical and clinical plans that will allow faster development of this product."

"I'd like to thank the PEI for their collaboration and guidance," continued Ben-Yedidia.

Scinai next intends to further fine tune dosing and drug half-life and conduct a longer duration follow on in-vivo animal study in late 2024, again, in collaboration with Prof. Gilhar of the Technion Israel Institute of Technology, complemented by a pre-clinical toxicology study before commencing a first-in-human clinical trial in late 2025. 

¹ Global Data Plaque Psoriasis: Global Drug Forecast and Market Analysis to 2030, November 2021

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with an innovative, de-risked pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing biological drug development, analytical methods development, clinical cGMP manufacturing, and pre-clinical and clinical trial design and execution services to early stage biotech drug development programs.

Company Contacts

Investor Relations | +972 8 930 2529 | ir@scinai.com 

Business Development | +972 8 930 2529 | bd@scinai.com 

Website: www.scinai.com

Forward-Looking Statements

 This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. All statements, other than statements of historical facts, are forward-looking statements. Examples of such statements include, but are not limited to, the timing of pre-clinical and clinical trials. These forward-looking statements reflect management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of Scinai Immunotherapeutics Ltd. Risks and uncertainties include, but are not limited to, the risk that Scinai will not conduct a follow on in-vivo animal study in late 2024, complemented by a pre-clinical toxicology study, will not conduct an in-human clinical trial, or that such studies and trial will be delayed; that; the risk of delay in, Scinai's inability to conduct, or the unsuccessful results of, its research and development activities, including the contemplated in-vivo studies and a clinical trial; the risk that Scinai will not be successful in expanding its CDMO business or in-license other NanoAbs; the risk that Scinai may not be able to secure additional capital on attractive terms, if at all; the risk that the therapeutic and commercial potential of NanoAbs will not be met or that Scinai will not be successful in bringing the NanoAbs towards commercialization; the risk of a delay in the preclinical and clinical trials data for NanoAbs, if any; the risk that our business strategy may not be successful; the risk that the European Investment Bank (EIB) may accelerate the financial facility under its finance contract with Scinai; the risk that the Company will not execute a definitive agreement with the EIB providing for revised terms of the Finance Contract with EIB; the risk that execution of such a definitive agreement will not resolve the deficiency notice of Nasdaq with respect to the Company's shareholders' equity; the risk that the Company will otherwise be unable to regain compliance and remain compliant with the continued listing requirements of Nasdaq irrespective of any such agreement with the EIB; Scinai's ability to acquire rights to additional product opportunities; Scinai's ability to enter into collaborations on terms acceptable to Scinai or at all; timing of receipt of regulatory approval of Scinai's manufacturing facility in Jerusalem, if at all or when required; the risk that the manufacturing facility will not be able to be used for a wide variety of applications and other vaccine and treatment technologies; and the risk that drug development involves a lengthy and expensive process with uncertain outcomes. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's Annual Report on Form 20-F filed with the Securities and Exchange Commission ("SEC") on May 15, 2024, and the Company's subsequent filings with the SEC. Scinai undertakes no obligation to revise or update any forward-looking statement for any reason.

Logo: https://mma.prnewswire.com/media/2310190/Scinai_Immunotherapeutics_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/scinai-immunotherapeutics-announces-positive-regulatory-feedback-from-the-pei-on-the-path-for-phase-12a-in-plaque-psoriasis-with-its-anti-il-17-nanoab-302203713.html

SOURCE Scinai Immunotherapeutics Ltd.

FAQ

What is the purpose of Scinai Immunotherapeutics' anti-IL-17A/F nanoAb (SCN-1) drug?

Scinai's anti-IL-17A/F nanoAb (SCN-1) is being developed for the treatment of mild to moderate plaque psoriasis, addressing the unmet need for more effective localized treatments with less frequent applications.

When is the Phase 1/2a clinical trial for Scinai's SCN-1 expected to begin?

The Phase 1/2a clinical trial for Scinai's SCN-1 is expected to commence in the second half of 2025, with results anticipated in 2026.

How many patients are expected to be included in Scinai's Phase 1/2a study for SCN-1?

Scinai's Phase 1/2a study for SCN-1 is expected to include approximately 24 plaque psoriasis patients.

What advantages does Scinai's SCN-1 offer over current plaque psoriasis treatments?

Scinai's SCN-1 is designed to be a biologic delivered locally into psoriatic lesions, potentially offering high specificity and potency with reduced risk of side effects compared to corticosteroids or systemic biologics, and requiring less frequent applications.

What positive feedback did Scinai (SCNI) receive from the PEI regarding their SCN-1 drug development?

Scinai received positive feedback from the PEI, including approval for toxicology studies in pigs, a combined Phase 1/2a trial design, and acceptance of their manufacturing process and specifications, potentially leading to significant time and cost savings in drug development.